Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Re-Approves Tysabri, Recommends Second-Line Use

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec expects to re-launch the multiple sclerosis therapy in July.

You may also be interested in...



Tysabri Liability: Biogen's Dialogue With FDA Helps Get Suit Tossed

Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.

Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS

Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.

Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS

Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS064435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel